Dr. William Williams reports

BRIACELL ANNOUNCES PROPOSED EFFECTIVE DATE OF SHARE CONSOLIDATION

Briacell Therapeutics Corp. has approved the consolidation of the company's issued and outstanding common shares on the basis of one postconsolidation common share for every 15 preconsolidation common shares. The consolidation is being implemented to ensure that the company continues to comply with the listing requirements of the Nasdaq Capital Market.

The consolidation is subject to approval by the Toronto Stock Exchange and is expected to become effective on Jan. 24, 2025, with the postconsolidation common shares commencing trading on the TSX and Nasdaq at market open on Jan. 29, 2025, subject to final confirmation from the TSX and Nasdaq. No fractional common shares will be issued in connection with the consolidation. Any fractional common shares arising from the consolidation will be deemed to have been tendered by its registered owner to the company for cancellation for no consideration. The exercise or conversion price and/or the number of common shares issuable under any of the company's outstanding convertible securities will be proportionately adjusted in connection with the consolidation.

It is anticipated that upon completion of the consolidation, the postconsolidation common shares will continue to trade on the TSX under the symbol BCT, and on Nasdaq under the symbol BCTX, under a new Cusip number: 107930208.

Shareholders of record as of the effective date will receive a letter of transmittal from Computershare Investor Services Inc., the transfer agent for the common shares, providing instructions for the exchange of their common shares as soon as practicable following the effective date.

Registered shareholders may also obtain a copy of the letter of transmittal by accessing the company's SEDAR+ profile. Until surrendered, each share certificate or direct registration system statement representing preconsolidation common shares will represent the number of whole postconsolidation common shares to which the holder is entitled as a result of the consolidation. No action is required by beneficial holders to receive postconsolidation common shares in connection with the consolidation. Beneficial holders who hold their common shares through intermediaries (that is, a broker, bank, trust company investment dealer or other financial institution) and who have questions regarding how the consolidation will be processed should contact their intermediaries with respect to the consolidation.

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.